San Diego—The I-CARE anterior chamber foldable phakic IOL (CORNEAL, Paris, France) seems to provide excellent anatomic and visual results 2 years after implantation.
San Diego—Phakic anterior chamber IOLs affect the biometric measurement of axial length, which results in clinically significant errors in IOL power calculations in patients who need to undergo cataract surgery. Gerald Zaidman, MD, described such a patient and offered suggestions for managing this complicated problem here at the American Society of Cataract and Refractive Surgery.
Los Angeles—Hypertension in a patient should raise a red flag for ophthalmologists because it may be associated with optic neuropathy. Anthony C. Arnold, MD, provided his pearls for the safe management of these patients.
Montreal—Acute third-, fourth-, or sixth-nerve palsies do not seem to be associated with myocardial infarctions (MI) and cerebrovascular accidents (CVA), but the development of one of these palsies is an indi- cation for an assessment of ischemic risk factors, according to Kashif Baig, MD, MBA.
Lausanne, Switzerland—Disorders of accommodation can be caused by disruption of neuroregulation. While many patients present with an insidious and mild accommodative insufficiency, often accompanying a systemic illness, the acute onset of severe and bilateral loss of accommodation is a more serious condition and may indicate the presence of a midbrain lesion.
Tampere, Finland-Both the M2 Single Use microkeratome and the M2 microkeratome with the new 90-?m head (Moria, Antony, France) have been performing well in clinical trials.
The HydroKeratome Waterjet System (Visijet Inc.), the first microkeratome that creates a LASIK flap using a continuous beam of ultra-high-pressure water instead of a metal blade, debuted at the 2003 annual meeting of the American Academy of Ophthalmology in Anaheim.
Rochester, NY-The Technolas 217 Z Zyoptix Personalized Vision Correction system (Bausch & Lomb) was approved by the FDA for use in the United States last month (see related news on Page 1). About 99% of patients expressed extreme satisfaction or satisfaction with the visual results afforded them by the system, which may increase patient interest in refractive surgery.
New York-Treatment with ranibizumab (Lucentis, Genentech) resulted in stable or im-proved vision in 97.5% of patients with wet age-related macular degeneration (AMD) over 6 months, according to the phase Ib/II trial results. Forty-five percent had more than a three-line gain in vision, said Jeffrey S. Heier, MD, a principal investigator in the clinical trial, who reported results at the annual meeting of the American Society of Retina Specialists.
Hradec Kralove, Czech Republic-The MemoryLens (CIBA Vision), a pre-rolled IOL, provides patients with very good postoperative outcomes and a low rate of posterior capsule opacification (PCO).